Skip to content
OpenCapital
Get started

Medtronic MDT Derivative Asset (Liability), Fair Value, Gross Asset (Liability)

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$101.86B-3.8%
Enterprise value$129.12B-3.2%
P/E21.2×-1.5×
P/S2.8×-0.4×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability.

The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medtronic's derivative asset (liability), fair value, gross asset (liability).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medtronic's derivative asset (liability), fair value, gross asset (liability)?
Medtronic (MDT) reported derivative asset (liability), fair value, gross asset (liability) of $149M in Q4 2025.
How has Medtronic's derivative asset (liability), fair value, gross asset (liability) changed year-over-year?
Medtronic's derivative asset (liability), fair value, gross asset (liability) decreased by 83.5% year-over-year, from $901M to $149M.
What is the long-term trend for Medtronic's derivative asset (liability), fair value, gross asset (liability)?
Over 4 years (2021 to 2025), Medtronic's derivative asset (liability), fair value, gross asset (liability) has grown at a -18.8% compound annual growth rate (CAGR), from -$193M to -$84M.